As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested in vivo and in vitro for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests.

中文翻译：

---

在2019年冠状病毒病（COVID-19）大流行管理中促进合理使用氯喹和羟氯喹的挑战和关怀：及时进行审查。

由于2019年冠状病毒疾病大流行（COVID-19），全球对治疗的需求迫切。由于其他感染性疾病的处方史，可及性和相对较低的成本等因素，已经在体内和体外测试了氯喹（CQ）和羟氯喹（HCQ）抑制严重致病病毒的能力。急性呼吸系统综合症冠状病毒2（SARS-CoV-2）。但是，即使研究人员注意到了这些药物的治疗潜力，也必须考虑合理使用CQ和HCQ的毒理学风险和必要的护理。这项研究提供了有关使用CQ预防或治疗COVID-19的主要毒理学和流行病学方面的信息，但主要是HCQ，它的毒性比CQ低，